User‐reported outcomes of long‐acting injectable PrEP with Cabotegravir: Real‐world experience from Milan
HIV Medicine · 2026
DOI: 10.1111/hiv.70162 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2026. Verfasst von Angelo Roberto Raccagni und 12 weiteren Autor:innen. Beteiligte Einrichtung: Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Pre-Exposure Prophylaxis, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Introduction
Oral HIV pre‐exposure prophylaxis (PrEP) is highly effective, but adherence and persistence are often limited by side effects, pill fatigue and stigma. Long‐acting injectable cabotegravir (CAB‐LA) offers a discreet, convenient alternative with the potential to improve user experience and HIV protection. Data on real‐world use in Europe remain limited. The aim is to describe user‐reported outcomes from individuals initiating CAB‐LA PrEP.
Methods
This is a prospective cohort study enrolling participants receiving CAB‐LA between November 2024 and July 2025 at a large teaching hospital in Milan, Italy (San Raffaele Institute). At each injection visit, user‐reported outcomes on satisfaction, adherence, perceived protection, quality of life and adverse events, including injection site reactions (ISRs) using a self‐reported survey developed for the study were collected.
Results
Eighty‐two participants (97.6% cis‐MSM, median age 41.4 years) were included (median injections 4, range 2–5). Most (95.1%) had prior oral PrEP experience; 26.9% reported previous oral PrEP side effects, and 15.4% poor adherence. CAB‐LA satisfaction remained high: at the fourth injection, 90.9% reported a positive overall opinion, and 84.4% felt more protected than on oral PrEP. Convenience and elimination of daily pill‐taking were valued by >94%. Self‐reported adherence improved in 75.3%. Side effects were mostly mild or unchanged compared with oral PrEP; systemic adverse events were uncommon and ISRs were generally minimal.
Conclusions
In this real‐world cohort, CAB‐LA PrEP was highly acceptable, well tolerated and associated with improved perceived adherence, convenience and HIV protection. These findings support CAB‐LA as a promising, user‐centred HIV prevention strategy, potentially overcoming key limitations of daily oral PrEP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vita-Salute San Raffaele University, Milan, Italy.
- Infectious Diseases Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
- Pharmacy Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Zitieren
APA
Raccagni, A. R., Passini, F., Lolatto, R., Capra, N., Bruzzesi, E., Muccini, C., Candela, C., Annicchiarico, G., di Gerardo, M., Puzziferri, R., Ferri, C., Castagna, A., & Nozza, S. (2026). User‐reported outcomes of long‐acting injectable PrEP with Cabotegravir: Real‐world experience from Milan. HIV Medicine. https://doi.org/10.1111/hiv.70162
Vancouver
Raccagni AR, Passini F, Lolatto R, Capra N, Bruzzesi E, Muccini C, et al. User‐reported outcomes of long‐acting injectable PrEP with Cabotegravir: Real‐world experience from Milan. HIV Medicine. 2026. doi:10.1111/hiv.70162
BibTeX
@article{Raccagni2026,
author = {Raccagni, Angelo Roberto and Passini, Flavia and Lolatto, Riccardo and Capra, Nicolò and Bruzzesi, Elena and Muccini, Camilla and Candela, Caterina and Annicchiarico, Gaetana and di Gerardo, Matteo and Puzziferri, Rossella and Ferri, Camilla and Castagna, Antonella and Nozza, Silvia},
title = {User‐reported outcomes of long‐acting injectable PrEP with Cabotegravir: Real‐world experience from Milan},
journal = {HIV Medicine},
year = {2026},
doi = {10.1111/hiv.70162}
}
EUVIMED